Advanced

Arsenic trioxide and neuroblastoma cytotoxicity.

Pettersson, Helen LU ; Karlsson, Jenny LU ; Pietras, Alexander LU ; Øra, Ingrid LU and Påhlman, Sven LU (2007) In Journal of Bioenergetics and Biomembranes 39(1). p.35-41
Abstract
The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in... (More)
The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Neuroblastoma, Arsenic trioxide, Cell death, APL, Bax
in
Journal of Bioenergetics and Biomembranes
volume
39
issue
1
pages
35 - 41
publisher
Kluwer
external identifiers
  • wos:000247375900005
  • scopus:34249945646
ISSN
1573-6881
DOI
10.1007/s10863-006-9058-6
language
English
LU publication?
yes
id
84850dd3-241f-44e5-a3db-217f05e56710 (old id 540000)
date added to LUP
2007-12-14 08:41:12
date last changed
2017-01-01 04:41:21
@article{84850dd3-241f-44e5-a3db-217f05e56710,
  abstract     = {The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells.},
  author       = {Pettersson, Helen and Karlsson, Jenny and Pietras, Alexander and Øra, Ingrid and Påhlman, Sven},
  issn         = {1573-6881},
  keyword      = {Neuroblastoma,Arsenic trioxide,Cell death,APL,Bax},
  language     = {eng},
  number       = {1},
  pages        = {35--41},
  publisher    = {Kluwer},
  series       = {Journal of Bioenergetics and Biomembranes},
  title        = {Arsenic trioxide and neuroblastoma cytotoxicity.},
  url          = {http://dx.doi.org/10.1007/s10863-006-9058-6},
  volume       = {39},
  year         = {2007},
}